Abstract: The disclosure relates to a compound of the formula (I) wherein R1 is H, C(O)—(C1-C6)alkyl or C(O)—O—(C1-C6)alkyl; R2 is OH, NH2, NH—(C1-C6)alkyl, NH—(C1-C4)alkylene-phenyl or NH—(C1-C4)alkylene-pyridyl; R3 and R4 are independently of each other H or OH, or R3 and R4 together are ?O; and m and n are independently of one another 0, 1 or 2; in any stereochemical form, or a mixture of any stereochemical forms in any ratio, or a physiologically acceptable salt thereof, obtainable from Actinomadura namibiensis (DSM 6313), and its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The disclosure relates to a compound of the formula (I) wherein m and n are independently of one another 0, 1 or 2, obtainable from Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The present invention relates to novel compounds, termed serpentemycins, of the formula (I) in which Y, R, R2, R3, R4, X, X2, X3, n, m and o are as defined in the specification, which are formed by the microorganism Actinomycetales sp. DSM 14865 during its fermentation, to chemical derivatives of the serpentemycins, to a process for preparing them, and to their use as pharmaceuticals, in particular for the treatment and prophylaxis of infectious bacterial diseases.

Abstract: The present invention provides novel phenalenone derivatives of formula (I) which are formed by the microorganism Penicillium herquei Bainer & Sartory, DSM 14142, during fermentation.

Abstract: The present invention relates to 2-phenylbenzofurans of formula (I) which are formed, during fermentation, by the microorganism Aspergillus flavipes ST003878 (DSM 15290), to a process for preparing them and to their use as pharmaceuticals for the treatment and/or prophylaxis of bacterial infectious diseases or mycoses.

Abstract: The invention relates to compounds of the formula I AcPhe-Aib-Aib-Aib-x-w-Leu-y-Aib-Hyp-Gln-z-Hyp-Aib-Pro-R ??(I) in which R is Phe-ol or Phe-al and w, x, y, and z have the following meanings: a) w is Gly or Ala; x is Aib and y and z are Iva; b) w is Gly; x, y and z are Iva; c) w is Gly; x and z are Aib and y is Iva; d) w is Gly; x, y and z are Aib; or e) w is Gly; x and y are Aib and z is Iva; or of the formula II AcPhe-Iva-Gln-Aib-lle-Thr-Aib-Leu-Aib-x-Gln-Aib-Hyp-Aib-Pro-Phe-Ser, ??(II) wherein x is Hyp or Pro, which are synthesized by Acremonium tubakii FH 1685 DSM 12774 during fermentation and released into the culture medium, a process for the isolation of the cephaibols from the culture medium, and their purification, and the use of the cephaibols as pharmacologically active compounds, in particular for the control of parasites.

Abstract: Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals. The present invention relates to the use of a compound of the formula (VI) for producing a pharmaceutical for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.

Abstract: The present invention relates to compounds of the formula which are formed during fermentation by the microorganism Coniochaeta ellipsoidea Udagawa, DSM 13856, or by one of its mutations and/or variants, and chemically derivatized if appropriate. The invention furthermore relates to a process for preparing compounds of the formula (I), and to their use as pharmaceuticals. In addition, the invention relates to the use of a compound of the formula (VI) for producing a pharmaceutical for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.

Abstract: The present invention relates to 2-phenylbenzofurans of formula (I) which are formed, during fermentation, by the microorganism Aspergillus flavipes ST003878 (DSM 15290), to a process for preparing them and to their use as pharmaceuticals for the treatment and/or prophylaxis of bacterial infectious diseases or mycoses.

Abstract: The invention relates to compounds of formula I in which R1, R2, E, X1, X2, and X3 have the meaning as described in the specification and claims, obtained by culturing Streptomyces species HAG 004107 (DSM 13381), and their physiologically tolerable salts and chemical equivalents. The invention furthermore relates to a process for the preparation of the cyclipostins, the microorganism HAG 004107 (DSM 13381), the use of the cyclipostins and their physiologically tolerable salts and chemical equivalents as pharmaceuticals, in particular as inhibitors of lipases, and pharmaceutical preparations which contain cyclipostin or a physiologically tolerable salt or equivalent thereof.

Abstract: The present invention relates to novel compounds, termed serpentemycins, of the formula (I) 1

Abstract: The present invention provides novel phenalenone derivatives of formula (I) which are formed by the microorganism Penicillium herquei Bainer & Sartory, DSM 14142, during fermentation. A process for their preparation, their use as pharmaceutical compositions, and their use for the treatment or prophylaxis of bacterial infections, mycoses, oncoses and rheumatic diseases are also disclosed and claimed.

Abstract: Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases in which high blood platelet aggregations occur.

Abstract: The invention relates to compounds of the formula I

Abstract: The invention relates to novel peptide derivatives, called memno peptides, of the formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8 and (A)n have the meaning herein, obtainable by cultivation of Memnoniella echinata FH2272, DSM 13195 or mutants and variants of this, a process for their preparation and the use of the compounds as pharmaceuticals, for example against cardiac insufficiency.

Abstract: The invention relates to a calcium salt of the compound of formula (II), where R1 is a straight-chain or branched, saturated or unsaturated aliphatic acyl radical having 8 to 22 carbon atoms, which can optionally be interrupted by or linked to one or more phenyl or cycloalkyl groups and optionally interrupted by oxygen. The invention also relates to a method for producing said calcium salt and to its use as a medicine.

Abstract: The present invention relates to compounds of the formula 1

Abstract: Compounds of the formula I 1

Abstract: The present invention relates to novel active substances (coniosetin and coniosetin derivatives) of the formula I which are produced by the microorganism Coniochaeta ellipsoidea Udagawa (DSM 13856) during fermentation, wherein R, R2, R3, R4, R5, X, X2, X3 and X4 have the meanings stated in the specification, to chemical derivatives of coniosetin, to a process for their preparation and to their use as pharmaceuticals.

Abstract: The invention relates to compounds of the formula I AcPhe-Aib-Aib-Aib-x-w-Leu-y-Aib-Hyp-Gln-z-Hyp-Aib-Pro-R  (I) in which R is Phe-ol or Phe-al and w, x, y, and z have the following meanings: a) w is Gly or Ala; x is Aib and y and z are Iva; b) w is Gly; x, y and z are va; c) w is Gly; x and z are Aib and y is Iva; d) w is Gly; x, y and z are Aib; or e) w is Gly; x and y are Aib and z is Iva; or of the formula II AcPhe-Iva-Gln-Aib-Ile-Thr-Aib-Leu-Aib-x-Gln-Aib-Hyp-Aib-Pro-Phe-Ser  (II), wherein x is Hyp or Pro, which are synthesized by Acremonium tubakii FH 1685 DSM 12774 during fermentation and released into the culture medium, a process for the isolation of the cephaibols from the culture medium, and their purification, and the use of the cephaibols as pharmacologically active compounds, in particular for the control of parasites.